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Abstract
Human papillomavirus type 16 (HPV-16) infections can in rare cases persist and cause lesions that may progress to cervical cancer. Cells in the
lesions are not permissive for virus production, nor are cervical cancer cells. The intracellular environment is such that it prevents production of the
highly immunogenic, viral structural proteins L1 and L2. One may speculate that inhibition of L1 and L2 expression is a prerequisite for persistence
and cancer progression. We have therefore investigated how expression of HPV-16 L1 is regulated. We found that the only splice site in the HPV-16
late region, which is used to produce L1 mRNAs, is under control of a splicing enhancer located in the 17 nucleotides immediately downstream of
the splice site. However, the function of this enhancer in cervical cancer cells is largely overshadowed by multiple splicing silencers in the late
region which bind to hnRNP A1. High levels of hnRNP A1 therefore inhibit HPV-16 L1 expression. Immunohistological analysis of cervical
epithelia revealed that hnRNPA1 is expressed primarily in the lower layers of the epithelium. hnRNPA1 is undetectable in terminally differentiated
cells that can express HPV-16 late genes, which supports the conclusion that high levels of hnRNP A1 inhibit HPV-16 L1 expression.
© 2007 Elsevier Inc. All rights reserved.
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Introduction
Human papillomaviruses (HPVs) are a group of small DNA
tumor viruses with strict tropism for epithelial cells (Howley,
1996; Shah and Howley, 1996; zur Hausen, 1999). HPV-16 is
the most prevalent genotype in cervical cancer, the second most
common cancer worldwide in women. While most HPV-16
infections are cleared by the host immune system less than 1
year after appearance, the infected cells can in rare cases persist
for decades and progress to cancer. The cancer cells lack the
ability to terminally differentiate and thus do not express the
immunogenic, late L1 and L2 capsid proteins (Ho et al., 1995).
We speculate that inhibition of L1 and L2 late gene expression
is a prerequisite for persistence and progression to cancer.
It has been shown that papillomavirus L1 and L2 mRNAs
contain inhibitory RNA elements that reduce late mRNA levels
in proliferating cells. These elements have been found in the late
3′UTR of BPV-1 (Furth and Baker, 1991), HPV-1 (Tan and
Schwartz, 1995), HPV-16 (Kennedy et al., 1991) and HPV-31
(Cumming et al., 2002) and the L1 and L2 coding regions
(Collier et al., 2002; Schwartz, 1998; Sokolowski et al., 1998;
Tan et al., 1995). Efficient polyadenylation of the early poly(A)
signal (pAE) also inhibits late gene expression. Our laboratory
has reported that this pAE is regulated by upstream elements in
the early 3′UTR and by downstream elements in the L2 coding
region (Oberg et al., 2005; Zhao et al., 2005). The early UTR
element interacts with Fip1, CstF-64, PTB and hnRNP C1/C2
and the downstream elements in the L2 coding region interact
with CstF-64 and hnRNP H (Oberg et al., 2003; Zhao et al.,
2005). We have shown that the levels of hnRNP H are reduced
in the layers with differentiated cell in normal cervical
epithelium in vivo, supporting a regulatory role for hnRNP H
in early polyadenylation and late gene expression of HPV-16
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(Oberg et al., 2005; Zhao et al., 2005). Terhune et al. have
identified a polyadenylation element in HPV-31 L2 that
interacts with CstF-64 (Terhune et al., 2001, 1999). The levels
of CstF-64 decrease as primary keratinocytes are induced to
differentiate in vitro, suggesting a role for CstF-64 in the
regulation of HPV-31 early mRNA polyadenylation (Terhune et
al., 2001, 1999).
HPVs make extensive use of alternative splicing. Alter-
natively spliced mRNAs have been mapped in several HPV
types and in particular in HPV-16 and HPV-31 (Baker and
Calef, 1997; Billakanti et al., 1996; Klumpp and Laimins,
1999; Milligan et al., 2007; Ozbun and Meyers, 1997). Many
of the splice sites in this region are suboptimal and are, or are
likely to be, under control of potent splicing silencers and
enhancers. Splicing regulatory elements have been identified in
bovine papillomavirus type 1 (BPV-1) (Baker, 1997; Zheng,
2004; Zheng et al., 1999, 1998, 2000a,b) and in HPV-16 (Rush
et al., 2005; Zhao et al., 2004). Previous results from our
laboratory identified a 48-nucleotide splicing silencer located
178 nucleotides downstream of the late 3′ splice site and
showed that it interacted with hnRNP A1 (Zhao et al., 2004).
The results presented herein are a continuation of previously
reported work in which we sought to identify the additional
regulatory RNA elements in L1 and determine their function.
We show that the first 17 nucleotides of the HPV-16 L1 coding
region contain a splicing enhancer interacting with a 55-kDa
protein. In dividing cells, this enhancer is overshadowed by
multiple hnRNP A1-binding splicing silencers located further
down in L1.
Results
Positive and negative splicing elements in the first 22
nucleotides of the HPV-16 L1 coding region
To investigate the effect of HPV-16 L1 RNA sequences on
late HPV-16 mRNA splicing, we introduced deletions in the L1
region of the CMV driven, subgenomic HPV-16 expression
plasmid named pBELDPU (Fig. 1) (Zhao et al., 2005). This
plasmid contains the strong CMV promoter immediately up-
stream of the E1 gene in the early region for high expression of
the HPV genes and lacks the early polyadenylation signal to
allow read-through into the late region for production of detect-
able levels of late mRNAs. Northern blots on RNA extracted
from transfected HeLa cells were hybridised to the L1 probe
that specifically detects late mRNAs (Fig. 1). As can be seen in
Fig. 2B, deletion of all L1 sequences between the AG of the 3′
splice site and position 514 in L1 as in p0, or all sequences
except the first 3 nucleotides as in p1–3, resulted in very
inefficient splicing. These results suggested that the 3′ splice
site required a splicing enhancer or that the L1 sequence down-
stream of position 514 (which was present in all plasmids in Fig.
2A) also inhibited splicing of the late mRNAs. In contrast, there
was a dramatic increase in splicing efficiency as the 17 first
nucleotides of L1 were inserted downstream of the splice ac-
ceptor (Fig. 2B), suggesting that the first 17 nucleotides contain
a splicing enhancer. Percentage splicing was calculated with
results from at least three independent transfections and mean
values with standard deviations are shown in the graphs (Fig.
Fig. 1. Schematic representation of the HPV-16 genome. Boxes indicate the protein coding regions. Numbers refer to nucleotide positions in the HPV-16R sequence
(Billakanti et al., 1996). The major p97 promoter and the differentiation dependent promoter p670 are indicated. Splice sites and polyadenylation signals are shown.
The structure of the pBELDPU (Zhao et al., 2005) expression plasmid is shown and the predicted late mRNAs are displayed. The L1 probe used in Northern blotting is
indicated. pAE, early polyA signal; pAL, late polyA signal, CMV, human cytomegalovirus immediate-early promoter; SD, 5′ss; SA, 3′ss.
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2B). Extending the 17 nucleotides to 22 instead caused a strong
inhibition of L1 splicing (Fig. 2B), demonstrating that splicing
inhibitory elements that counteracted the effect of the first 17
nucleotides had been included. The corresponding mutant 22-
nucleotide L1 sequence, derived from a previously described L1
mutant sequence (Collier et al., 2002; Zhao et al., 2004), did not
inhibit splicing (Fig. 2B), which is in line with our previous
results which showed that these mutations destroyed splicing
inhibitory elements but did not negatively affecting splicing
(Zhao et al., 2004). The first 17 nucleotides of L1 are pyrimidine
rich, whereas the 18–22-sequence has a more balanced nucleo-
tide composition (Fig. 2A). Interestingly, mutations at positions
4, 5, 6 and 9 in p1–22mut did not affect the positive splicing
elements in the first 17 nucleotides, indicating that a splicing
enhancer was located in the UGGCUGCC sequence, between
position 10 and 17 (Fig. 2A). We also transfected plasmids p1–
17, p1–22 and p1–22mut into C33A cells and 293 cells with
similar results (Fig. 2C). In conclusion, positive splicing ele-
ments were located in the first 17 nucleotides of L1 and negative
splicing elements were located in the first 22 nucleotides of L1.
Sequence specific activation of HPV-16 late mRNA splicing by
a splicing enhancer in the first 17 nucleotides of L1
To study the 17-nucleotide enhancing sequence further, pair-
wise nucleotide substitutions were introduced in p1–17 (Fig.
3A). As can be seen in Fig. 3B, the enhancer was not affected by
the substitutions in mut3, but the substitutions in mut5 and mut6,
which had the strongest effect, caused a reduction in splicing
from 79% to 34% and 55%, respectively (Fig. 3B). These results
support the conclusion above that the enhancer is located
between nucleotides positions 10 and 17 of L1. However, since
Fig. 2. (A) Schematic representation of pBELDPU-derived (Zhao et al., 2005) plasmids. The deletions introduced in L1 are indicated. Plasmid names are on the left.
Numbers refer to nucleotide positions in HPV-16 L1, position 1 being A in the AUG. Sequences of the 5-end of the L1 sequences present in plasmids p1–3, p1–9, p1–
17, p1–22 and p1–22mut are displayed. Introduced mutations are bold, underlined and capitalised. (B) Northern blots of total RNA extracted from HeLa cells
transfected with the indicated plasmids and hybridised to the L1 probe (Fig. 1). Spliced mRNA as a percentage of total late RNA is shown in the graph below the gel.
Numbers represent mean values with standard deviations from at least three independent transfections with the same plasmid. (C) Northern blots of total RNA
extracted from HeLa cells transfected with the indicated plasmids in 293 cells and C33A cells.
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none of the mutants completely inhibited splicing, we could not
exclude that the 17-nucleotide L1 sequence stimulated splicing
both through a sequence specific mechanism and by increasing
the distance between the 3′ splice site and potential downstream
splicing inhibitory elements in L1. To provide further evidence
for a sequence specific activation of splicing by the first 17
nucleotides of L1, we replaced these 17 L1 nucleotides with the
same sequence in antisense orientation, resulting in p1–17(AS)
(Fig. 3A). In contrast to p1–17, this plasmid produced primarily
unspliced late mRNAs (Fig. 3C), confirming that an RNA
element in the first 17 nucleotides of L1 specifically enhanced
splicing to the late 3′ splice site (Tables 1 and 2).
To confirm the presence of positive splicing elements in the
HPV-16 L1 coding region, we inserted a larger, 1–177 L1 wt
fragment in sense and antisense orientation upstream of the 178–
366 sequence in the previously described plasmid pPL178–366
(Zhao et al., 2004) (Fig. 4A), resulting in pPL1–177–366 (Fig.
4A). Plasmid pPL178–366 produces primarily unspliced late
mRNAs as a result of a splicing silencer located between L1
positions 178 and 226, as reported earlier (Zhao et al., 2004) (Fig.
4B). However, insertion of sequence 1–177 in sense orientation
as in pPL1–177–366 (Fig. 4A) caused a significant increase in
mRNA splicing (Fig. 4B), confirming that the first 177
nucleotides of L1 contained elements that enhanced splicing,
whereas insertion of the same sequence in antisense orientation as
in pPL1–177(AS)–366 (Fig. 4A) failed to promote splicing (Fig.
4B). We also inserted a mutant 1–177 sequence derived from the
previously described L1 mutant (Zhao et al., 2004), in which
splicing inhibitory sequences had been destroyed by point muta-
tions, into pPL178–366, resulting in p1–177(mut)–366 (Fig.
4A). The mutant 1–177 also induced late mRNA splicing as
expected (Fig. 4C). Taken together, these results demonstrated
that the 5′-end of L1 contains elements that enhanced splicing of
HPV-16 L1 mRNAs in a sequence specific manner.
The 17-nucleotide HPV-16 L1 splicing enhancer stimulates
splicing in vitro
To test if the 17-nucleotide sequence could stimulate splicing
in vitro, the first 17 nucleotides of L1 were inserted immediately
Fig. 3. (A) Schematic representation of plasmid pBELDPU (Zhao et al., 2005). The sequences inserted immediately downstream of the AG of the L1 3′ splice site are
displayed. Numbers refer to nucleotide positions in L1, starting at the A in the AUG. Plasmid names are on the left. (B and C) Northern blots of total RNA extracted
from HeLa cells transfected with the indicated plasmids. Blots were hybridised to the L1 probe (Fig. 1). Spliced mRNA as a percentage of total late RNA in each lane is
indicated at the bottom of the gel. Numbers represent mean values with standard deviations from at least three independent transfections with the same plasmid.
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downstream of the 3′ splice site in the previously described,
adenovirus-derived pTA plasmid (Collier et al., 2002; Zhao et
al., 2004) (Fig. 5A). The pTA plasmid produces an mRNA that
can be spliced in vitro to a certain extent (Figs. 5A and B).
Insertion of the first 17 nucleotides of HPV-16 L1 enhanced
splicing in vitro (Fig. 5B), demonstrating that this region con-
tains a splicing enhancer that could enhance splicing of a hete-
rologous RNA in vitro. Surprisingly, the 22-nucleotide se-
quence also promoted splicing (Fig. 5B). The reason for this is
that it contains the positive element in the first 17 nucleotides of
L1 and that the inhibitory element located in the 22-nucleotide
sequence is dependent on downstream L1 sequences that are
Table 1
Sequences of PCR oligonucleotides used to make pBEL-derived plasmids
Oligonucleotide Sequence (5′→3′)
L2R GGGCCCTTCTGATCCTTCTATAG
#L1AS GGATCCCTGAAAAAAAATATGGTAAAC
16L1(3)AS GGATCCCATCTGAAAAAAAATATGGTAAACG
16L1(9)AS GGATCCAAGAGACATCTGAAAAAAAATATGG
16L1(17)AS GGATCCGGCAGCCAAAGAGACATCTGAAAAAAAATATGG
16L1(22)AS AAGCTTGGATCCCACTAGGCAGCCAAAGAG
16L1(22)ASmut AAGCTTGGATCCCGCTGGGCAGCCACAG
16L1(129)AS AAGCTTGGATCCCAAGTAGTCTGGATG
16L1M(129)AS AAGCTTGGATCCCAGCAG
16L1(22)ASmut1 AAGCTTGGATCCCACTAGGCAGCCAAAGGCTCAT
16L1(22)ASmut2 AAGCTTGGATCCCGCTGGGCAGCCACAGAGACAT
16L1(22)mut3AS GGATCCCACTAGGCAGCCAATCAGA
16L1(22)mut4AS GGATCCCACTAGGCAGCGTAAGAGA
16L1(22)mut5AS GGATCCCACTAGGCACGCAAAGAGA
16L1(22)mut6AS GGATCCCACTAGGGTGCCAAAGAGA
16L1(22)mut7AS GGATCCCACTATTCAGCCAAAGAGA
16L1(22)mut8AS GGATCCCAGAAGGCAGCCAAAGAGA
16L1(22)mut9AS GGATCCGACTAGGCAGCCAAAGAGA
16L1(22)mut10AS GGATCCCACTAGGCAGCCACAGAGA
16L1(22)mut11AS GGATCCCACTGGGCAGCCAAAGAGA
16L1(22)mut12AS GGATCCCGCTAGGCAGCCAAAGAGA
16L1(17)mut3AS GGATCCGGCAGCCAATCAGACATCTGAAAA
16L1(17)mut4AS GGATCCGGCAGCGTAAGAGACATCTGAAAA
16L1(17)mut5AS GGATCCGGCACGCAAAGAGACATCTGAAAA
16L1(17)mut6AS GGATCCGGGTGCCAAAGAGACATCTGAAAA
16L1(17)mut7AS GGATCCTTCAGCCAAAGAGACATCTGAAAA
L1START(SalI) GTCGACCAGCGCGCCAAGATGTC
16L1(1/ClaI)S ATCGATATGTCTCTTTGGCTGCC
16L1(177/ClaI)AS ATCGATTTTGTTATTGTTAGG
16L1(177/SalI)AS GTCGACTTTGTTATTGTTAGG
16L1M(177AS)ClaI ATCGATCTTGTTGTTGTTAGGCTTC
17AS(AS) GGATCCATGTCTCTTTGGCTGCCCTGAAAAAAAAATGGTAAAC
16L1(366)AS AAGCTTGGATCCTAAAGGATGGCCACTAATGC
Table 2
Sequences of the oligonucleotides used to make in vitro RNA synthesis plasmids
Oligonucleotide Sequence (5′→3′)
L1 start (s) GTCGACATGTCTCTTTGGCTGCCTAGTG
L1Mstart(SalI) GTCGACATGAGCCTGTGGCTGCCCAGCG
16L1–17(S) cATGTCTTTTGGCTGCCg
16L1–17(AS) gatccGGCAGCCAAAGACATggtac
16L1–22(S) cATGTCTCTTTGGCTGCCTAGTGg
16L1–22mut(AS) gatccCGCTGGGCAGCCACAGGCTCATggatc
WTsilencer1×4(S) cTAGTGATAGTGATAGTGATAGTGAg
WTsilencer1×4(AS) gatccTCACTATCACTATCACTATCACTAggtac
MUTsilencer1×4(S) cCAGCGGCAGCGGCAGCGGCAGCGGg
MUTsilencer1×4(AS) gatccCCGCTGCCGCTGCCGCTGCCGCTGggtac
PThnRNPA1(S) cTATGATAGGGACTTAGGGTGa
PThnRNPA1(AS) agcttCACCCTAAGTCCCTATCATAggtac
(Ad)AG17(AS) ACGCGTGGCAGCCAAAGAGACATCTGTGGAAAAAAAAG
(Ad)AG22(AS) ACGCGTCACTAGGCAGCCAAAGAGACATCTGTGGAAAAA
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absent in this plasmid (see below Fig. 6). Since these down-
stream L1 sequences were absent in pTA22, only the enhancer
element was operational. We concluded that the first 17 nucleo-
tides of L1 contain a splicing enhancer that promotes splicing of
heterologous 3′ splice sites in vitro.
The identified splicing enhancer is not required for utilisation
of the HPV-16 L1 3′ splice site in the absence of silencers
Although the results presented above established that the
first 17 nucleotides of L1 contain a splicing enhancer, se-
quence analysis of the L1 3′ splice site shows that it conforms
well to the consensus 3′ splice site. We therefore wished to test
if the L1 3′ splice site was functional in the absence of the
enhancer. The L1 sequence from 514 to 1512 was inserted in
the antisense orientation in p1–3, resulting in p3A (Fig. 6A).
In contrast to p1–3, plasmid p3A produced primarily spliced
mRNAs (Fig. 6B), suggesting that the L1 3′ splice site could
function in the absence of enhancer elements in L1, if only
the downstream L1 sequences were altered as well, as in
p3A (Fig. 6A). Similar results were obtained if the L1 se-
quence downstream of position 3 in p1–3 was replaced by
the CAT sequence, as in p1–3CAT (Fig. 6C). The control
plasmid p1–514CAT (Fig. 6A) produced primarily unspliced
mRNA as expected, due to the presence of a longer L1 sequence
(Fig. 6C).
Fig. 4. (A) Schematic diagram of the pBEL-pAEPL plasmid (Zhao et al., 2004). A polylinker including a small sequence from the pCRII-TOPO cloning vector
(Invitrogen) was inserted into L1, thereby replacing nucleotides 23 to 513 of L1 (numbering starts at the A in the AUG of L1). The indicated wt andmutant L1 sequences
(Zhao et al., 2004) of various length were inserted into the polylinker asMluI–BamHI or SalI–MluI fragments. (B and C) Northern blots on total RNA extracted from
HeLa cells transfected with the indicated plasmids. The blots are probed with the L1 probe (Fig. 1). Spliced mRNA as a percentage of total late RNA in each lane is
indicated at the bottom of each gel. Numbers represent mean values with standard deviations from at least three independent transfections with the same plasmid.
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To test the idea that the splicing silencer in the first 22
nucleotides of L1 was functionally dependent on downstream
L1 sequences, L1 sequences downstream of positions 17 or 22
were replaced by CAT, resulting in p17CAT and p22CAT,
respectively (Fig. 6A). The p17CAT plasmid produced prim-
arily spliced mRNAs, as expected (Fig. 6C). The efficient
splicing of p22CAT (Fig. 6C) demonstrated that the inhibitory
sequences in the first 22 nucleotides of L1 were unable to inhibit
splicing in isolation (Fig. 6C). These results therefore
established that the splicing inhibitory element located in the
first 22 nucleotides of L1 was functionally dependent on down-
stream L1 sequences. In addition, the HPV-16 3′ splice site was
only dependent on the enhancer when the splicing silencers in
L1 were present, or active, indicating that the role of the en-
hancer is to counteract the effect of downstream splicing silen-
cers in L1.
Sequence specific inhibition of HPV-16 late mRNA splicing by
a splicing inhibitor in the first 22 nucleotides of L1
The results presented above demonstrated that a splicing
silencer was located in the first 22 nucleotides of L1. Although
it was dependent on downstream L1 sequences, it dominated
over the splicing enhancer in the first 17 nucleotides of L1. We
therefore wished to characterise the splicing inhibitor in the first
22 nucleotides of L1 further. Plasmid p1–22 and p1–22mut
differ on 6 positions (Fig. 7A). These substitutions were intro-
duced three by three in the wt 22-sequence, resulting in p1–
22mut1 and p1–22mut2 (Fig. 7A). The results showed that the
3′-most mutations inactivated the silencer whereas the 5′-most
three did not (Fig. 7B). Introduction of the three inactivating
mutations one by one as in p1–22mut10, p1–22mut11 and p1–
22mut12 (Fig. 7A) revealed that all three substitutions nega-
tively affected the silencer (Fig. 7B). In addition, the negative
effect on the silencer by the substitution at position 9 in p1–
22mut10 (Fig. 7A) indicated that the silencer in the 3′-end of the
22-nucleotide sequence extended upstream of position 17 in L1
(Fig. 7B). We concluded that the 18–22-sequence was an
important part of the splicing silencer in HPV-16 L1.
Next, pair-wise substitutions were introduced in the 22-
nucleotide sequence (Fig. 7A). The majority of the mutations
that caused an increase in splicing clustered to the 3′-end of the
22 sequence (Fig. 7B). However, the increase in splicing caused
by the dinucleotide substitution at positions 7 and 8 in p1–
22mut3 (Fig. 7B), together with the data obtained with p1–
22mut10, which demonstrated the importance of nucleotide
position 9 (Fig. 7B), indicated that sequences in this upstream
region also contributed to the function of the splicing silencer.
In conclusion, these results demonstrated that the splicing inhi-
bitory element in the first 22 nucleotides of L1 acted in a
sequence specific manner.
UV cross-linking of a 35- and 65-kDa protein to the splicing
silencer and a 55-kDa protein to the splicing enhancer
sequence in the HPV-16 L1 RNA
Having established that the enhancer and the silencer in the
first 22 nucleotides of L1 both acted in a sequence specific
manner, we wished to identify factors that interacted specifi-
cally with the two RNA elements. However, UV cross-linking
of radiolabelled 1–17WT, 1–22WT and 1–22mut L1 RNAs
(Fig. 8A) to nuclear extract revealed that all RNAs interacted
with the same 55-kDa protein (Fig. 8B). Since we had shown
above that the splicing silencer in the first 22 nucleotides of L1
was dependent on downstream sequences, we extended the L1
probe to L1 position 129 and performed UV cross-linking with
RNAs 1–17WT and 1–129WT (Fig. 8A). We identified two
factors (p35 and p65) that bound to 1–129WT L1 sequence, but
not to the 1–129mut or 1–17WT RNAs (Fig. 8C), suggesting
that they were involved in splicing inhibition. The 129WT L1
sequence inhibits splicing in transient transfection experiments,
Fig. 5. (A) Schematic representation of the adenovirus derived pTA plasmid
(Zhao et al., 2004), pTA1–17WT and pTA1–22WT that were used for in vitro
synthesis of preRNA substrates for the in vitro splicing reactions. The numbering
of the inserted HPV-16 L1 fragments starts at the A in the L1 AUG. T7, T7 RNA
polymerase promoter; SD, adenovirus 5′ splice site; SA, adenovirus 3′ splice site.
(B) In vitro splicing reactions using RNA derived from the indicated plasmids.
The splicing products are indicated.
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whereas the 1–129mut L1 sequence does not (Fig. 6D). In
conclusion, binding of the 35-kDa and 65-kDa proteins corre-
lated with splicing inhibition, whereas binding of the 55-kDa
protein correlated with splicing enhancement.
UV cross-linking of the 35-kDa protein to a multimer of the
18–22 L1 mRNA sequence
To explain the results of the mutational analysis in Fig. 7,
which identified a splicing inhibitory sequence between nuc-
leotide position 18–22 in L1 and the lack of specific UV cross-
linking to the 1–22WT sequence compared to 1–17WT, we
reasoned that a weak binding site for an inhibitory factor was
present in the 3′-end of the first 22 nucleotides of HPV-16 L1,
between nucleotide position 18 and 22, and that multiple
binding sites for this factors were needed to obtain efficient
binding. To test this idea, a multimer of the 18–22 L1 sequence
4×(18–22WT) and a multimer of the 18–22 mutant L1 se-
quence 4×(18–22mut) were generated and UV cross-linked to
nuclear extract (Fig. 8A). As can be seen, a protein of the same
size as the 35-kDa protein that interacted specifically with the
1–129WT L1 sequence also interacted with the 18–22WT L1
multimer 4×(18–22WT), but not with the 18–22 mutant L1
multimer 4×(18–22mut) (Fig. 8D). These results suggested that
Fig. 6. (A) Schematic representation of plasmids p1–3, p3A, p1–129, p1–129mut, p3CAT, p17CAT, p22CAT and p514CAT. (B–D) Northern blots of total RNA
extracted from HeLa cells transfected with the indicated plasmids. Blots were hybridised to the L1 probe (Fig. 1) in panels B and D, and the CAT probe (A) in panel C.
Spliced mRNA as a percentage of total late RNA in each lane is indicated at the bottom of each gel. Numbers represent mean values with standard deviations from at
least three independent transfections with the same plasmid.
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it was the 35 kDa factor that inhibited splicing. To confirm that
the 35-kDa protein binding to the 4×(18–22WT) and the 1–
129WT RNA was the same protein, a competition experiment
was performed. The results revealed that the 4×(18–22WT)
multimer competed efficiently with the 1–129WT RNA for the
35 kDa factor, whereas the 18–22 mutant multimer 4×(18–
22mut) did not (Fig. 8E). This competition occurred with
efficiency comparable to that of the 1–129WT RNA competitor
(Fig. 8E), demonstrating that the 4×(18–22WT) and the 1–
129WT RNA interacted with the same 35 kDa factor.
UV cross-linking of hnRNP A1 to all HPV-16 RNA sequences
that bind the 35-kDa protein
To investigate if the 35-kDa protein that interacted with the
4×(18–22WT) and the 1–129WT RNA was the 35 kDa
hnRNP A1 protein previously shown to bind to the 178–
226 L1 silencer (Zhao et al., 2004), UV cross-linking react-
ions to 1–129WT RNA were subjected to competition with
178–226WT or 178–226mut competitors (Zhao et al., 2004).
As can be seen, the 178–226WT sequence competed efficient-
ly with the 1–129WT probe for the 35-kDa protein, whereas
the 178–226mut RNA did not (Fig. 8E). These results
indicated that the 35-kDa protein was hnRNP A1. Recombi-
nant GST-hnRNP A1 also cross-linked to the 1–129WT and
4×(18–22WT) RNAs, but not to the 1–129mut or 4×(18–
22mut) RNAs (Fig. 8F). The 178–226WT and 178–226mut
RNAs (Zhao et al., 2004) served as controls (Fig. 8F). The
results revealed that all HPV-16 wt L1 sequences that cross-
linked to the 35 kDa factor in nuclear extracts also cross-
linked to GST-hnRNP A1, whereas the mutant L1 sequences
did not (Fig. 8F).
Fig. 7. (A) Schematic representation of plasmid pBELDPU (Zhao et al., 2005). The sequences inserted immediately downstream of the AG in the 3′ splice site in
pBELDPU are displayed. Numbers refer to nucleotide positions in L1, starting at the A in the AUG. Plasmid names are on the left. (B) Northern blot of total RNA
extracted fromHeLa cells transfected with the indicated plasmids. Blots were hybridised to the L1 probe (Fig. 1). Spliced mRNA as a percentage of total late RNA in each
lane is indicated at the bottom of the gel. Numbers represent mean values with standard deviations from at least three independent transfections with the same plasmid.
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Fig. 8. (A) Sequences of the in vitro transcribed HPV-16 wild type and mutant L1 RNAs from the indicated plasmids. The mutant nucleotide positions are capitalised
and underlined. The T7 promoter is indicated. (B–D) UV cross-linking of nuclear extract to the indicated radiolabelled RNAs. The p35, p55 and p65 proteins cross-
linking to the HPV-16WT L1 sequence are indicated to the right. (E) UV cross-linking of nuclear extract to radiolabelled 1–129WT RNA in the absence or presence of
the indicated, serially diluted unlabelled competitor RNAs. (F) UV cross-linking of recombinant GST-hnRNPA1 to the indicated radiolabelled RNAs. (G) UV cross-
linking of nuclear extract to an optimal hnRNP A1-binding site in the absence or presence of serially diluted, unlabelled competitor RNAs.
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We also cross-linked nuclear extract to a high affinity hnRNP
A1-binding site (Fig. 8G) and investigated if the 1–129WT
RNA competed with the hnRNPA1-binding site for the 35 kDa,
hnRNPA1 protein. As expected, the 129WT L1, but not the 1–
129mut L1, sequence competed for hnRNPA1 (Fig. 8G). Note
that hnRNP H that has been shown previously to bind to the
hnRNPA1 high affinity site (5) is also detected here (Fig. 8G).
Although some competition for p55 was seen with 1–129WT
RNA, it is less efficient than competition for the 35 kDa hnRNP
A1 (Fig. 8G). In conclusion, these results confirmed that
hnRNP A1 binds specifically to multiple HPV-16 L1 RNA
sequences with splicing inhibitory activity.
Expression of hnRNP A1 is cell differentiation dependent in
cervical squamous epithelia
The results described above indicated that hnRNP A1 inhi-
bits splicing into the L1 region by binding to multiple splicing
silencers that override the effect of the splicing enhancer in the
first 17 nucleotides of L1. These results also suggested that high
levels of hnRNP A1 inhibit the use of the L1 3′ splice site and
prevent L1 expression and predicted that hnRNP A1 levels
should be high in cervical epithelial cells that are not permissive
for HPV-16 L1 production, for example cells in the lower layer
of the cervical epithelium. In contrast, cells in the superficial
levels of the epithelium that are permissive for HPV-16 L1
expression and virus production should not express hnRNPA1.
Staining of sections from normal cervical epithelium with anti-
serum against hnRNPA1 revealed that high levels of hnRNPA1
were found in the lower layers of the epithelium, whereas
hnRNP A1 was undetectable in the superficial layers (Fig. 9).
These results supported the conclusion that hnRNP A1 is a
negative regulator of HPV-16 L1 expression.
Discussion
hnRNP A1 has been shown to be involved in regulation of
splicing of a multitude of cellular and viral mRNAs (Cartegni et
al., 2002; Zheng, 2004). In general hnRNPA1 acts by inhibiting
the use of a certain splice site. This effect is antagonised by SR
proteins, primarily ASF/SF2 (Mayeda and Krainer, 1992). Se-
veral models for the action of hnRNP A1 have been proposed.
Binding of hnRNP A1 to a high affinity site on HIV-1 pre-
mRNAs has been shown to cause multimerisation and filling up
of multiple low affinity hnRNP A1 biding sites on the mRNA
(Damgaard et al., 2002). In one case, multimerisation is occur-
ring in combination with binding of hnRNP A1 to an intronic
splicing silencer overlapping the branch point of the 3′ splice
site (Damgaard et al., 2002; Tange et al., 2001). These multiple
hnRNP A1 interactions with the pre-mRNA prevented binding
of U2 snRNP to the branch point, thereby inhibiting splicing
(Tange et al., 2001). This effect was counteracted by ASF/SF2
and to some extent by SC35. Another HIV-1 splice site was
shown to be under control of an exonic splicing silencer over-
lapping and enhancer. These elements were binding to hnRNP
A1 and SC35, respectively (Zahler et al., 2004). In this case, a
direct competition between the two factors determined the effect
on splicing (Zahler et al., 2004). Binding of hnRNPA1 to HIV-1
mRNAs has also been shown to prevent binding of U2AF65 to
the upstream polypyrimidine tract of a 3′ splice site, either by
inhibiting U2AF65 directly or indirectly by inhibiting binding
of U2AF35 (Domsic et al., 2003). The results shown here with
binding of hnRNPA1 to multiple sites within HPV-16 L1 com-
bined with the previously published results demonstrating that
binding of hnRNP A1 to at least one of these sequences causes
inhibition of splicing in vitro allow us to speculate that multi-
merisation of hnRNP A1 and binding to multiple sites on the
mRNAmay result in inhibition of splicing by inhibiting binding
of either U2 snRNP or U2AF to the HPV-16 mRNA.
The first 17 nucleotides of L1 is relatively pyrimidine rich
and contains a potential binding site (UCUU) for the splicing
regulatory factor named polypyrimidine tract binding protein
(PTB) (Perez et al., 1997). However, mutations that altered the
potential PTB binding site UCUU did not affect mRNA splicing
and we have been unable to show that the 55-kDa protein is
PTB. Another interesting feature of this sequence is that it dis-
plays a significant homology with an HIV-1 sequence present in
an ESS element termed ESS2p (Jacquenet et al., 2001). While
the HPV-16 sequence in the first 17 nucleotides of L1 is UUG-
GCUGCC, HIV-1 M isolates has the consensus of UUGGGU-
GUC, HIV-1 N has UUGGCUGCC and HIV-1 O has UUGGA-
UGCC. It was shown that hnRNP H binds to the HIV-1 M
(Jacquenet et al., 2001). However, it is unclear if hnRNP H
binds to the other HIV-1 sequences since they all lack the triple
G motif that appears to be crucial for hnRNP H binding to an
RNA substrate (Caputi and Zahler, 2001). Similarly, the HPV-
16 RNA sequence lacks the triple G motif and we were unable
to show specific binding to hnRNP H. The HPV-16 sequence
and the HIV-1 M sequence differ in only two positions, one of
which is the third G in the triple G motif. This position is not
conserved amongst the three HIV-1 M, N and O groups either.
The sequence similarity and the close proximity of the se-
quences to 3′ splice site argue for a conserved role of these
sequences in gene expression. This is further supported by the
relatively high conservation of this sequence amongst HPV
types in different genera. It will be of interest to determine the
identity of the factor that interacts with the first 17 nucleotides
of the HPV-16 L1 sequence. The enhancer appears to be located
Fig. 9. Immunohistochemical detection of hnRNP A1 in normal cervical epi-
thelium. The epithelial sections were stained with mouse monoclonal antibody
specific for hnRNP A1 (clone 9H10, Abcam).
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between nucleotide positions 10 and 17 in L1. In HPV-16, this
sequence is UGGCUGGCC, whereas in many other HPV types
a remarkably well conserved sequence is UGGCGGCC (Bill-
akanti et al., 1996).
Although we show that the HPV-16 L1 3′ splice site func-
tions perfectly well in the absence of downstream L1 sequences,
probably due to its relatively long uninterrupted polypyrimidine
tract (9 consecutive pyrimidines), we cannot rule out that
hnRNPA1 competes with SR proteins binding to the late HPV-
16 mRNAs. In this respect it is of interest to point out that ASF/
SF2, which can antagonise the effect of hnRNP A1, has been
shown to interact with the UTR of late HPV-16 mRNAs
(McPhillips et al., 2004; Mole et al., 2006). Although the func-
tional significance of this interaction between ASF/SF2 and the
viral mRNA remains unknown, ASF/SF2 could potentially
affect binding of hnRNP A1 negatively, thereby promoting
HPV-16 late gene expression. Interestingly, differentiating mu-
rine erythroblasts exhibit activation of exon 16 splicing of the
cytoskeletal protein 4.1R mRNA as the hnRNP A/B levels
decrease in a differentiation dependent manner (Hou et al.,
2002). It would be interesting to investigate the expression of
hnRNP A1 in relation to HPV-16 genes in a differentiating en-
vironment to determine the role of hnRNPA1 in the HPV-16 life
cycle.
Materials and methods
Plasmid constructions
Plasmid constructions are described in a supplementary
section.
Transfections, RNA extraction and Northern blotting
Transfections were performed in HeLa cells according to the
Fugene 6 method (Roche Molecular Biochemicals). Total
RNAs were extracted from the transfected cells at 24 h post
transfection according to the RNeasy Mini protocol (Qiagen).
All plasmids were analysed in a minimum of three independent
transfections. All quantitations represent mean values from at
least three independent transfections. The data variation in each
transfection experiment was less than 20%. Northern blot
analysis was performed as described previously (Collier et al.,
2002). The L1 and CAT probes are indicated in Figs. 1 and 3.
All Northern blots were quantified in a Bio-Rad phosphor-
imager (GS-250).
UV cross-linking and preparation of cellular extracts and
recombinant hnRNP A1
UV cross-linking and synthesis of radiolabelled RNA were
performed as previously described (Spångberg et al., 2000).
HeLa cell nuclear extracts were prepared according to the
method of Dignam et al. (1983). GST-hnRNPA1 was prepared
as described previously (Sokolowski et al., 1999). Twenty mi-
crograms of nuclear extract or fifty nanograms of recombinant
hnRNP A1 was used for each UV cross-linking.
In vitro splicing
In vitro splicing experiment was performed as previously
described (Zhao et al., 2004). 70,000 cpm radiolabelled capped
pre-mRNA substrate and 8 μg of HeLa nuclear extract were
used in the in vitro splicing reaction.
Immunohistochemical detection of hnRNP A1
Immunohistochemical detection was performed as described
previously (Oberg et al., 2005) except that 100 μl of mouse
monoclonal antibody specific for hnRNP A1 (clone 9H10,
Abcam) or anti-hnRNPA1 antiserum Y-15, Santa Cruz Biotech-
nologies, was used at a dilution of 1:25. Antigen retrieval was
carried out using Trilogy pressure cooker method (Cell Marque)
as described by the manufacturer.
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